Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: Mechanism, epidemiology, management, and prevention

Inflammatory Bowel Diseases

Volumn 24, Issue 10, 2018, Pages 2173-2182

  Colombel, Jean Frédéric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Herpes zoster; JAK; Shingles; Tofacitinib; Ulcerative colitis

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; TOFACITINIB; VARICELLA ZOSTER VACCINE; ANTIVIRUS AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

AGE; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; EXPERIENCE; HERPES ZOSTER; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; JAK-STAT SIGNALING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION; ULCERATIVE COLITIS; VACCINATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MANAGEMENT; DRUG EFFECT; PROGNOSIS; VARICELLA ZOSTER VIRUS; VIROLOGY;

ANTIVIRAL AGENTS; COLITIS, ULCERATIVE; DISEASE MANAGEMENT; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; JANUS KINASE INHIBITORS; JANUS KINASES; PIPERIDINES; PROGNOSIS; PYRIMIDINES; PYRROLES;

EID: 85055212024     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy150     Document Type: Review

References (81)

1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255-263.
2. Côté-Daigneault J, Peerani F, MacMahon E, et al. Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary. Inflamm Bowel Dis. 2016;22:2538-2547.
3. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
4. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26-33.
5. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66:1-28.
6. Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9:439-444.
7. Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
8. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998;225:92-99.
9. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.e1.
10. Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162.
11. De Vries LCS, Wildenberg ME, De Jonge WJ, et al. The future of janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017;11:885-893.
12. Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet. 2017;389:1741-1755.
13. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756-1770.
14. O'Shea JJ. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis. 2004;63:ii67-ii71.
15. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-287.
16. Sharfe N, Dadi HK, O'Shea JJ, et al. Jak3 activation in human lymphocyte precursor cells. Clin Exp Immunol. 1997;108:552-556.
17. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev. 2005;18:70-80.
18. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784-4790.
19. Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNSS Drugs. 2015;29:565-575.
20. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun. 1981;32:24-27.
21. Salam N, Rane S, Das R, et al. T cell ageing: effects of age on development, survival & function. Indian J Med Res. 2013;138:595-608.
22. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234-243.
23. Abendroth A, Arvin AM. Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol. 2001;13:27-39.
24. Ku CC, Zerboni L, Ito H, et al. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med. 2004;200:917-925.
25. Furie R, Khamashta M, Merrill JT, et al; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severesystemiclupuserythematosus.ArthritisRheumatol.2017;69:376-386.
26. Khamashta M, Merrill JT, Werth VP, et al; CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-1916.
27. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341-357.
28. Moodley D, Yoshida H, Mostafavi S, et al. Network pharmacology of JAK inhibitors. Proc Natl Acad Sci U S A. 2016;113:9852-9857.
29. Valenzuela F, Papp KA, Pariser D, et al. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol. 2015;15:8.
30. Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133-1138.
31. Marra F, Lo E, Kalashnikov V, et al. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofw205.
32. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-1349.
33. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490.
34. Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241-258.
35. Long MD, Martin C, Sandler RS, et al. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420-429.
36. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-2533.
37. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325-334.
38. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737-744.
39. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al; BIOBADASER 2.0 Study Group. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69:1751-1755.
40. Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol. 2012;132:726-729.
41. Buccoliero G, Lonero G, Romanelli C, et al. Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol. 2010;33:271-274.
42. Elwir SM, Shaffer CC, Arvan SW, et al. Disseminated varicella zoster virus infection with encephalitis in a UC patient receiving infliximab. Gastroenterol Hepatol (N Y). 2013;9:54-56.
43. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
44. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960-1968.
45. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88-95.
46. Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46-55.
47. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009-1019.
48. Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057-1064.
49. Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68:2857-2866.
50. Fleischmann R, Mysler E, Hall S, et al; ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457-468.
51. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:1185-1192.
52. Sandborn WJ, Feagan BG, Panes J, et al. Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn's disease: results from Celest. Gastroenterol. 2017;152:1308.
53. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266-275.
54. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675-2684.
55. Friesen KJ, Chateau D, Falk J, et al. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infect Dis. 2017;17:69.
56. Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302-309.
57. Javed S, Kamili QU, Mendoza N, et al. Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-α. J Med Virol. 2011;83:2051-2055.
58. Bing N, Zhou H, Zhang B, et al. Genome-wide trans-ancestry meta-analysis of herpes zoster in RA and Pso patients treated with tofacitinib. Arthritis Rheumatol. 2015;67:Abstract 566.
59. US Food and Drug Administration. Zostavax FDA approval. October 10, 2017. https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm136941.htm. Accessed May 02, 2018.
60. Electronic Medicines Compendium (eMC). Zostavax SmPC. August 18, 2017. https://www.medicines.org.uk/emc/product/6101. Accessed May 02, 2018.
61. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30; quiz CE2.
62. Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729-731.
63. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-49.
64. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1-26.
65. Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003;125:1583-1590.
66. Rahier JF, Magro F, Abreu C, et al; European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468.
67. Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12:540-546.
68. Wasan SK, Zullow S, Berg A, et al. Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis. 2016;22:1391-1396.
69. Khan N, Shah Y, Trivedi C, et al. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther. 2017;46:668-672.
70. Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309-318.
71. Pfizer Inc. XELJANZ summary of product characteristics. March 22, 2017. https://www.medicines.org.uk/emc/product/2500. Accessed May 02, 2018.
72. Winthrop KL, Neal J, Hrycaj P, et al. Evaluation of influenza and pneumococcal vaccine responses in rheumatoid arthritis patients using tofacitinib. Ann Rheum Dis. 2013;72:107.
73. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687-695.
74. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969-1977.
75. Levin MJ, Oxman MN, Zhang JH, etal; Veterans Affairs Cooperative StudiesProgram Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responsesinelderlyrecipientsof aherpeszostervaccine.JInfectDis.2008;197:825-835.
76. Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013;208:1386-1390.
77. US Food and Drug Administration. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for intramuscular injection, highlights of prescribing information. July 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581605.pdf. Accessed November 6, 2017.
78. Health Canada. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for injection. October 2017. http://ca.gsk.com/media/1350785/patientinformation-english.pdf. Accessed November 6, 2017.
79. Cunningham AL, Lal H, Kovac M, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-1032.
80. Lal H, Cunningham AL, Godeaux O, et al; ZOE-50 Study Group. Efficacy of an adju-vanted herpes zoster subunit vaccine in older adults. NEnglJMed. 2015;372:2087-2096.
81. GlaxoSmithKline. GSK presents positive results from phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting. June 21, 2017. http://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-re-sults-from-phase-iii-revaccination-study-of-its-candidate-shingles-vaccine-shin-grix-at-cdc-s-advisory-meeting/. Accessed October 17, 2017.